Sunday, July 22, 2018

Medical errors in nursing home patients



Medication errors (MEs) result in preventable harm to nursing home (NH) residents and pose a significant financial burden. Institutionalized older people are particularly vulnerable because of various organizational and individual factors. This systematic review reports the prevalence of MEs leading to hospitalization and death in NH residents and the factors associated with risk of death and hospitalization. A systematic search was conducted of the relevant peer-reviewed research published between January 1, 2000, and October 1, 2015, in English, French, German, or Spanish examining serious outcomes of MEs in NHs residents. Eleven studies met the inclusion criteria and examined three types of MEs: all MEs (n = 5), transfer-related MEs (n = 5), and potentially inappropriate medications (PIMs) (n = 1). MEs were common, involving 16–27% of residents in studies examining all types of MEs and 13–31% of residents in studies examining transfer-related MEs, and 75% of residents were prescribed at least one PIM. That said, serious effects of MEs were surprisingly low and were reported in only a small proportion of errors (0–1% of MEs), with death being rare. Whether MEs resulting in serious outcomes are truly infrequent, or are underreported because of the difficulty in ascertaining them, remains to be elucidated to assist in designing safer systems.



Saturday, July 21, 2018

Update on hypertrophic cardiomyopathy


Form a recent review:

Most clinicians would recommend ICD therapy if any one of the five major risk factors is present, although recent debate has focused on whether at least two risk factors are required…

Previous cardiac arrest/ventricular tachycardia (secondary prevention)
Family history of premature sudden cardiac death
Left ventricular wall thickness greater than or equal to 30 mm
Previous episodes of documented NSVT (greater than or equal to 3 beats, rate greater than or equal to 120 bpm)
Unexplained syncope

Concerning treatment in general:

Many treatment options are currently available for HCM patients. This ranges from no treatment; lifestyle modifications, e.g. avoiding competitive sports in all patients with HCM; use of pharmacological agents e.g. beta blockers, calcium channel blockers, and diuretics; to surgical septal myectomy and transcoronary alcohol septal ablation of the myocardium (i.e. the creation of a limited septal infarct by direct injection of alcohol into a septal perforator artery) for individuals with significant left ventricular outflow tract obstruction with symptoms unresponsive to drug therapy. The single most important advance in the clinical management of HCM has involved the use of ICD therapy in the prevention of sudden death [12] . Recent studies indicate that treatment of individuals at highest risk of sudden death with an ICD is the most definitive form of therapy in preventing sudden death and easily surpasses empirically-based preventative strategies previously used in HCM, e.g. amiodarone and beta blockers.

Friday, July 20, 2018

Improved understanding of bicuspid aortic valve disease


A recent article cites findings coming out of the newly established International Bicuspid Aortic Valve Disease Registry.

New guidelines for ECG interpretation in athletes


Reviewed here.

Great info if you can access it. Unfortunately it is behind a pay wall and the graphics and text are too complicated for me to give key points here.


Monday, June 18, 2018

Don’t conflate type 2 MI and NSTEMI!


Confusion remains wide spread despite the publication of this distinction years ago. But now, according to this piece in Circulation, the coding world is finally catching up. ICD 10 now has a code for type 2 MI. Here are some of my take home points:

A type 2 MI is not an acute coronary syndrome.

On initial presentation the distinction is based on clinical circumstances and may occasionally be difficult.

Further investigation usually makes the distinction clear by the end of the hospitalization.

Type 2 MI, though a distinct category, is not a primary single entity in that it is always secondary to something else, one or more of many known conditions. For this reason it is heterogeneous and there are no guidelines for type 2 MI per se. Its treatment always consists of management of the underlying conditions that are altering the myocardial oxygen supply demand balance.

Though ICD 10 now recognizes the distinction, type 2 MI has yet to be excluded from certain performance and regulatory categories for MI due to acute coronary syndrome.

Those who conflate NSTEMI and type 2 MI not only expose their ignorance (or disregard) of the classification and pathophysiology of MI but also risk subjecting patients to inappropriate and potentially harmful treatments. An example is provided in the article.

Sunday, June 17, 2018

Metformin monotherapy versus dual therapy with the addition of a sodium glucose co-transporter 2 inhibitor (SGLT-2)



Highlights

•Type 2 Diabetes Mellitus (T2DM) is a current global threat.
•Sodium-glucose co-transporter 2 inhibitor is a new approach for T2DM management.
•Combined therapy of SGLT2 inhibitor and metformin is more effective.

Abstract

Background

Type 2 Diabetes Mellitus (T2DM) is a chronic disorder and its treatment with only metformin often does not provide optimum glycemic control. Addition of sodium glucose cotransporter 2 inhibitor (SGLT2) will improve the glycemic control in patients on metformin alone. In this study, an attempt is made to investigate the combined therapy of SGLT-2 with metformin in managing T2DM in terms of lowering HbA1c and body weight and monotherapy using metformin alone in HbA1c and body weight reduction.

Objectives

To compare the clinical effectiveness of combined therapy using SGLT2 inhibitor and metformin with monotherapy using metformin alone in HbA1c and body weight reduction.

Method

A systematic review of the randomized controlled trials has been carried out and Cochrane risk of bias tool was used for the quality assessment. Patient, Intervention, Comparison and Outcomes (PICO) technique is used to select the relevant articles to meet the objective.

Results

The studies used in this article are multicenter, double-blinded randomized controlled trials on SGLT2 inhibitors with methformin, there were a total of 3897 participants, with a range of 182 to 1186 individual study size were included. Studies showed that combined therapy were more effective in HbA1c and body weight reduction as compared to monotherapy.


Saturday, June 16, 2018

Possible health benefits of dietary magnesium


Friday, June 15, 2018

Methamphetamine related heart failure: rising prevalence, distinct phenotype



Hypothesis: We hypothesized that in a VA population over a 15 year period, we would observe a rising prevalence of MethHF in admitted patients, along with a unique phenotype.

Methods: Among 9588 patients with diagnosis of heart failure treated at San Diego VA Medical Center in between 2005-2015, 480 were identified to have history of methamphetamine abuse as determined by ICD-9 diagnosis code and/or urine toxicology screen as well as a diagnosis code of heart failure. Demographic, diagnostic, and clinical characteristics of MethHF and heart failure patients without methamphetamine use (HF) were compared. ..

Results: From 2005-2015, the prevalence of methamphetamine usage among patients with heart failure increased linearly (Figure 1). A preliminary cohort comparison demonstrated MethHF had similar ejection fraction and BNP levels but trends toward increased troponin levels, more atrial fibrillation, and a higher GFR. MethHF patients had a greater risk of ER visits (2.3 per year vs 0.5 per year, p=0.01) and a trend towards a greater risk of all-cause hospital readmission...